Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03679234 · ClinicalTrials.gov registry record · NA
Impact of Infant Formula on Caregiver-perceived Intolerance
A NA study, sponsored by Société des Produits Nestlé (SPN).
- Completed
- Registry status
- NA
- Development phase
- 51
- Enrollment target
NCT03679234: Completed NA study, sponsored by Société des Produits Nestlé (SPN).
NCT03679234 is a NA study that has completed, run by Société des Produits Nestlé (SPN). The registered enrollment target is 51 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03679234, a NA study, has completed, sponsored by Société des Produits Nestlé (SPN).
- COMPLETED
- Registry status
- NA
- Development phase
- 51 participants
- Enrollment target
Study Summary
Understand the impact of switching to a commercially available infant formula on gastrointestinal symptoms
Primary Outcome
Study personnel will administer questionnaire
Interventions
- OTHER Routine infant formula
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2018-09-24 |
| Est. Completion | 2019-04-01 |
| Phase | NA |
What the finished NCT03679234 record still lists
NCT03679234 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 51 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 1 intervention - of which Routine infant formula is the first listed.
NCT03679234 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03679234 about?
NCT03679234 is a clinical study titled "Impact of Infant Formula on Caregiver-perceived Intolerance". Understand the impact of switching to a commercially available infant formula on gastrointestinal symptoms
What is the current status of trial NCT03679234?
This trial is currently completed. It is a NA study. The enrollment target is 51 participants. The study started on 2018-09-24. Estimated completion is 2019-04-01.
What interventions are being tested in trial NCT03679234?
The interventions under investigation include: Routine infant formula (OTHER).
Who is sponsoring clinical trial NCT03679234?
This trial is sponsored by Société des Produits Nestlé (SPN), which has 53 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03679234's enrollment target sits among peer trials
51 1279th of 2000 higher than 722 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02701153 · 51 participants · NA
Phase II Study of 5-Day Hypofractionated Preoperative Radiation Therapy for Soft Tissue Sarcomas: Expansion Cohort
- NCT03663790 · 51 participants · NA
Effects of Gait Retraining on Lower Extremity Biomechanics
- NCT03874052 · 51 participants · Phase 1
Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
- NCT04704661 · 51 participants · Phase 1
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI